News & Events

Highlighted Events

Praxis Precision Medicines Announces Plan to Start PRAX-222 (formerly RC-222) EMBRAVE Clinical Study following FDA clearance

January 2023

Invitae’s Real World Ciitizen Data Utilized in PRAX-222 (formerly RC-222) IND Filing

September 2022

PRAX-222 (formerly RC-222)Receives Rare Pediatric Disease and Orphan Drug Designation

January 2021

RogCon Development Partner Praxis Precision Medicines to Present on PRAX-222 (formerly RC-222) Program at SCN2A Family Virtual Conference

September 2020

PRIOR HEADLINES

Alex Nemiroff and Dr. Steven Petrou Presenting at Epilepsy Precision Medicine Conference

RogCon Sponsoring The SCN2A Family and Professional Conference

Dr. Steven Petrou Presents Data on Antisense Oligonucleotide Development Program for SCN2A Epilepsy at World Orphan Drug Congress

AES Late-Breaking Abstract Presentation: Antisense oligonucleotide therapy for SCN2A gain-of-function epilepsies

Prior Press Releases

RogCon and Prometheus Research Enter into Partnership to Support International Natural History Study on SCN2A Mutations

January 14, 2019

RogCon Biosciences Launches with Late-Breaking Presentation on SCN2A Epilepsy at the 2018 AES Meeting

December 1, 2018

In The News

Antisense Oligonucleotide Therapy For SCN2A Gain-of-Function Epilepsies: AES Poster

December 1, 2018

Relationship of Electrophysiological Dysfunction and Clinical Severity in SCN2A-Related Epilepsies.

September 13, 2018

SCN2A mutation in an infant presenting with migrating focal seizures and infantile spasm responsive to a ketogenic diet.

September 1, 2018

Dominant SCN2A Mutation Causes Familial Episodic Ataxia and Impairment of Speech Development.

August 30, 2018

Nav1. 2 haplodeficiency in excitatory neurons causes absence-like seizures in mice.

July 19, 2018

The autism-associated gene Scn2a plays an essential role in synaptic stability and learning.

July 10, 2018

Progress in Understanding and Treating SCN2A-Mediated Disorders.

July 1, 2018

Dynamic action potential clamp predicts functional separation in mild familial and severe de novo forms of SCN2A epilepsy.

June 12, 2018

Diagnostic outcomes for genetic testing of 70 genes in 8565 patients with epilepsy and neurodevelopmental disorders.

April 14, 2018

FOXD3 inhibits SCN2A gene transcription in intractable epilepsy cell models.

April 1, 2018

Neurotransmitters and Sodium Channelopathies; Possible Link?

November 10, 2017

Opposing effects on NaV1. 2 function underlie differences between SCN2A variants observed in individuals with autism spectrum disorder or infantile seizures.

August 1, 2017

Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders.

May 1, 2017

Mutations of voltage-gated sodium channel genes SCN1A and SCN2A in epilepsy, intellectual disability, and autism.

October 10, 2016

Mutation screening of SCN2A in schizophrenia and identification of a novel loss-of-function mutation.

April 26, 2016

SCN2A encephalopathy A major cause of epilepsy of infancy with migrating focal seizures.

August 25, 2015

Beyond the Ion Channel: ILAE Genetics Commission Blog

August 11, 2015

Differential effects of common variants in SCN2A on general cognitive ability, brain physiology, and messenger RNA expression in schizophrenia cases and control individuals.

June 7, 2014